Effectiveness and safety of adalimumab biosimilar in patients with inflammatory bowel disease

CONCLUSIONS: Between originator adalimumab and biosimilar-start cohorts, no differences were observed, between originator adalimumab and switch cohorts, no significant differences were found either, and with the pre- and post-switch to biosimilar comparison, 2 of the 9 patients experienced AEs after the switch. The biosimilar showed a favorable safety profile (one patient with a serious adverse effect (rash) with biosimilar discontinued treatment) and no significant changes to clinical or biochemical parameters were observed after the switch.PMID:38570210 | DOI:10.1016/j.farma.2024.01.002

Source: Farmacia Hospitalaria - April 3, 2024 Category: Drugs & Pharmacology Authors: Jaime E Poquet-Jornet In és Ibáñez-Sala Teresa Garrigues-Pelufo Adri án Munilla-Das Antonio Valdivia-P érez Francisco Javier Carrera-Hueso Source Type: research